JPH10175820A - Suppressant for melanogenesis and beautifying and whitening cosmetic - Google Patents

Suppressant for melanogenesis and beautifying and whitening cosmetic

Info

Publication number
JPH10175820A
JPH10175820A JP35418396A JP35418396A JPH10175820A JP H10175820 A JPH10175820 A JP H10175820A JP 35418396 A JP35418396 A JP 35418396A JP 35418396 A JP35418396 A JP 35418396A JP H10175820 A JPH10175820 A JP H10175820A
Authority
JP
Japan
Prior art keywords
suppressant
present
melanogenesis
hydroxyethyl
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP35418396A
Other languages
Japanese (ja)
Inventor
Takeshi Ikemoto
毅 池本
Hiroko Nakatsugawa
弘子 中津川
Tomohiro Yokota
朋宏 横田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP35418396A priority Critical patent/JPH10175820A/en
Priority to TW86115777A priority patent/TW464501B/en
Publication of JPH10175820A publication Critical patent/JPH10175820A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To prepare the subject suppressant, having effects on the suppression of melanogenesis and reduction in skin pigmentation such as dermal stains or ephelides and having high safety by including a specific compound therein. SOLUTION: This suppressant for melanogenesis comprising a compound represented by the formula (R is a residue of monosaccharides or oligosaccharides) [e.g. p-(2-hydroxyethyl)phenyl-D-glucoside (the α- and '- isomers)] is prepared by condensing, e.g. 2-(4-hydroxyphenyl)ethyl alcohol with an acetylated saccharide in an organic solvent (e.g. toluene) in the presence of a catalyst (e.g. boron trifluoride) and then eliminating the acetyl groups in the presence of an alkali. Oils and fats, humectants, pigments, coloring matters, surfactants, antioxidants, ultraviolet light absorbers, preservatives, etc., as necessary, can be formulated with 0.05-10.0wt.% resultant suppressant and prepared as a medicine, (quasi-drug), a cosmetic, etc. A beautifying and whitening cosmetic is especially preferably prepared.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、メラニン生成抑制
剤、ならびにそれを含有した美白化粧料に関する。さら
に詳しくは、安全性が高く、化粧品、医薬部外品および
医薬品などに、紫外線に曝露されたことによって生じた
皮膚の色素沈着(しみ、そばかすなど)を改善する効果
を目的として配合できるメラニン生成抑制剤に関する。
TECHNICAL FIELD The present invention relates to a melanin production inhibitor and a whitening cosmetic containing the same. More specifically, melanin production is highly safe and can be combined with cosmetics, quasi-drugs, and pharmaceuticals for the purpose of improving skin pigmentation (stains, freckles, etc.) caused by exposure to ultraviolet light. Related to inhibitors.

【0002】[0002]

【従来の技術】しみ、そばかすは、メラニンの生成と排
泄のバランスが崩れ、表皮細胞内にメラニンが過剰に蓄
積したものである〔三島豊他、フレグランスジャーナ
ル、17(1)、p25、1989〕。これらの原因
は、炎症、ホルモンのバランス、遺伝的要因などさまざ
まであるが、紫外線の影響により助長される。増加した
色素沈着を緩和するのが美白剤である。このうち、美白
化粧品用に応用されているものとしては、アスコルビン
酸、またはその誘導体、プラセンタエキス、ハイドロキ
ノン誘導体(アルブチン)、コウジ酸等が知られてお
り、これらを配合した美白化粧料が提案されている。
BACKGROUND OF THE INVENTION Blots and freckles are those in which the balance between production and excretion of melanin is lost and melanin is excessively accumulated in epidermal cells [Yutaka Mishima et al., Fragrance Journal, 17 (1), p25, 1989]. . These causes can be varied, including inflammation, hormonal balance, and genetic factors, but are facilitated by the effects of ultraviolet radiation. Whitening agents alleviate the increased pigmentation. Among them, ascorbic acid or its derivatives, placenta extract, hydroquinone derivative (arbutin), kojic acid and the like are known as those applied for whitening cosmetics, and whitening cosmetics containing these are proposed. ing.

【0003】しかし、これらの美白剤は、メラニンの生
成を抑制する効果はあるものの、安全性に問題を残すも
のが多かった。さらに、これらの美白剤を配合した美白
化粧料を塗布しても、しみ、そばかすの改善において必
ずしも十分満足すべき効果が得られなかった。
[0003] However, although these whitening agents have an effect of suppressing the production of melanin, many of them have a problem in safety. Further, even when a whitening cosmetic containing these whitening agents is applied, a sufficiently satisfactory effect in improvement of spots and freckles was not necessarily obtained.

【0004】メラニンは、表皮基底層にあるメラノサイ
ト(色素細胞)内の細胞小器官であるメラノソームで生
成される。その後、ケラチノサイト(表皮細胞)へ受け
渡され、ケラチノサイト内で分解を受けながら角化の流
れに乗り、最終的には角化細胞の落屑とともに皮膚から
消失する(清寺真、現代皮膚科学大系、3B、p97、
中山書店、1982)。
[0004] Melanin is produced by melanosomes, the organelles in melanocytes (pigment cells) in the basal layer of the epidermis. After that, it is transferred to keratinocytes (epidermal cells), rides on the flow of keratinization while undergoing decomposition within the keratinocytes, and finally disappears from the skin with desquamation of the keratinocytes (Masayoshi Kiyoji, a modern dermatologist, 3B, p97,
Nakayama Shoten, 1982).

【0005】したがって、しみ、そばかすの原因は、複
雑であるので、単にメラニンの生成を抑制するのみでな
く、色素沈着の原因となる炎症を防止したり、新陳代謝
を活発化することによりメラニンが皮膚内部に留まるこ
とを防止したり、紫外線等によってダメージを受けた皮
膚機能を回復させたりすることが重要である。
[0005] Therefore, since the cause of spots and freckles is complex, melanin not only suppresses the production of melanin, but also prevents inflammation which causes pigmentation and activates metabolism to cause melanin to develop in the skin. It is important to prevent it from staying inside and to restore skin function damaged by ultraviolet rays or the like.

【0006】[0006]

【発明が解決しようとする課題】本発明の目的は、安全
性が高く、優れたメラニン生成抑制作用を有するメラニ
ン生成抑制剤を提供するとともに、紫外線に曝露された
ことによって生じた皮膚の色素沈着(しみ、そばかすな
ど)を改善する効果に優れた美白化粧料を提供すること
にある。
SUMMARY OF THE INVENTION An object of the present invention is to provide a melanin production inhibitor which is highly safe and has an excellent melanin production inhibitory action and, at the same time, pigmentation of skin caused by exposure to ultraviolet rays. An object of the present invention is to provide a whitening cosmetic having an excellent effect of improving (spots, freckles, etc.).

【0007】[0007]

【課題を解決するための手段】本発明者らは、上記事情
を鑑み、メラニン生成抑制効果を有し、かつ高い安全性
を有するメラニン生成抑制剤を開発すべく鋭意検討した
結果、特定の配糖体が強いメラニン生成抑制作用と、紫
外線に曝露されたことによって生じた皮膚の色素沈着
(しみ、そばかすなど)を改善する効果も共に有してい
ることを見いだし、本発明を完成した。すなわち、本発
明は、下記一般式で示される特定の配糖体およびそれを
含有することを特徴とする美白化粧料である。
Means for Solving the Problems In view of the above circumstances, the present inventors have conducted intensive studies to develop a melanin production inhibitor having a melanin production inhibitory effect and having high safety. The present inventors have found that a saccharide has both a strong melanin production inhibitory effect and an effect of improving skin pigmentation (stains, freckles, etc.) caused by exposure to ultraviolet rays, and completed the present invention. That is, the present invention is a specific glycoside represented by the following general formula, and a whitening cosmetic containing the same.

【0008】[0008]

【化2】 Embedded image

【0009】(但し、式中Rは単糖類、少糖類の残基か
ら選ばれる基である。)
(Wherein R is a group selected from the residues of monosaccharides and oligosaccharides)

【0010】[0010]

【発明の実施の形態】以下、本発明の実施の形態につい
て詳述する。
Embodiments of the present invention will be described below in detail.

【0011】本発明の配糖体を得る方法としては、アル
ブチンの合成方法として既に公知の方法(USP第32
01385号)を用いて得ることができる。例えば、ト
ルエンなどの有機溶媒中において2−(4−ヒドロキシ
フェニル)エチルアルコールとアセチル化糖を三フッ素
化ホウ素やオキシ塩化リンなどを触媒として縮合した
後、アルカリ存在下にアセチル基を脱離することにより
本発明の配糖体を白色の粉末結晶として容易に得ること
もできる。
As a method for obtaining the glycoside of the present invention, a method already known as a method for synthesizing arbutin (USP No. 32)
No. 01385). For example, after condensing 2- (4-hydroxyphenyl) ethyl alcohol and acetylated sugar in an organic solvent such as toluene using boron trifluoride or phosphorus oxychloride as a catalyst, an acetyl group is eliminated in the presence of an alkali. Thereby, the glycoside of the present invention can be easily obtained as white powder crystals.

【0012】本発明で用いられる糖残基は、還元性の単
糖類または少糖類であり、具体的にはグルコース、ガラ
クトース、キシロース、マンノース、N−アセチルグル
コサミン等の単糖類、マルトース、セロビオース、ゲン
チビオース等の二糖類などを挙げることができる。な
お、本発明の配糖体にはα結合およびβ結合を有する異
性体が存在するが、そのどちらでも、あるいはそれらの
混合物として用いることができる。
The saccharide residue used in the present invention is a reducing monosaccharide or oligosaccharide, and specifically, monosaccharides such as glucose, galactose, xylose, mannose and N-acetylglucosamine, maltose, cellobiose, gentibiose. And the like. The glycoside of the present invention has an isomer having an α bond and a β bond, and either of them or a mixture thereof can be used.

【0013】本発明で用いられる具体的な配糖体として
は、p−(2−ヒドロキシエチル)フェニル−D−グル
コシド(αおよびβ体)、p−(2−ヒドロキシエチ
ル)フェニル−D−ガラクトシド(αおよびβ体)、p
−(2−ヒドロキシエチル)フェニル−D−キシロシド
(αおよびβ体)、p−(2−ヒドロキシエチル)フェ
ニル−D−マルトシド(αおよびβ体)などを挙げるこ
とができる。
Specific glycosides used in the present invention include p- (2-hydroxyethyl) phenyl-D-glucoside (α and β forms) and p- (2-hydroxyethyl) phenyl-D-galactoside (Α and β forms), p
-(2-hydroxyethyl) phenyl-D-xyloside (α and β forms), p- (2-hydroxyethyl) phenyl-D-maltoside (α and β forms) and the like can be mentioned.

【0014】本発明のメラニン生成抑制剤は、医薬品・
医薬部外品・化粧品などに配合することができる。特
に、色素沈着を改善する美白化粧料に配合することが好
適である。なお、本発明のメラニン生成抑制剤は、外用
組成物あるいは内服用組成物にも配合できる。
[0014] The melanin production inhibitor of the present invention comprises
It can be incorporated into quasi-drugs and cosmetics. In particular, it is suitable to be incorporated into a whitening cosmetic which improves pigmentation. In addition, the melanin production inhibitor of the present invention can be blended into a composition for external use or a composition for internal use.

【0015】本発明のメラニン生成抑制剤の配合量は使
用する系によって様々で、一概には言えないが、以下の
実施例から明らかなように、既存のこの種の物質と同等
もしくはかなり低濃度でよく、0.05〜10.0重量
%を用いることができる。
The amount of the melanin production inhibitor of the present invention varies depending on the system to be used, and cannot be specified unconditionally. And 0.05 to 10.0% by weight can be used.

【0016】本発明の美白化粧料には、必要に応じて、
通常、医薬品、医薬部外品、化粧品等の皮膚外用剤に配
合される油脂類、保湿剤類、顔料類、色素類、界面活性
剤類、抗酸化剤類、紫外線吸収剤類、防腐剤類、水溶性
高分子類、樹脂類等を適宜配合することができる。
The whitening cosmetic of the present invention may optionally contain
Oils and fats, moisturizers, pigments, pigments, surfactants, antioxidants, ultraviolet absorbers, preservatives, which are usually incorporated in skin external preparations such as pharmaceuticals, quasi-drugs, and cosmetics And water-soluble polymers, resins and the like can be appropriately compounded.

【0017】また、軟膏類、ローション類、乳液類、ク
リーム類、パック類、顆粒類等の任意の剤型とすること
ができる。
[0017] Also, any dosage form such as ointments, lotions, emulsions, creams, packs, granules and the like can be used.

【0018】[0018]

【実施例】次に、本発明の配糖体によるメラニン生成抑
制作用の効果を明らかにするための実施例として、合成
例、試験例、配合製剤例(美白化粧料)を示す。
EXAMPLES Next, as examples for clarifying the effect of the glycoside of the present invention on the inhibitory action of melanin production, synthetic examples, test examples and blended preparation examples (whitening cosmetics) will be shown.

【0019】合成例1:p−(2−ヒドロキシエチル)
フェニル−D−グルコシドの合成合成方法の具体例とし
て、以下にp−(2−ヒドロキシエチル)フェニル−D
−グルコシドの合成方法を示すが、本発明で用いるメラ
ニン生成抑制剤を合成する方法はこの限りではない。
Synthesis Example 1: p- (2-hydroxyethyl)
Synthesis of phenyl-D-glucoside As a specific example of the synthesis method, p- (2-hydroxyethyl) phenyl-D
A method for synthesizing a glucoside will be described, but the method for synthesizing the melanin production inhibitor used in the present invention is not limited thereto.

【0020】40mlの脱水トルエンと、10mlの脱水エ
チルエーテルの混合溶液に2.76g (16.8mmo
l)の2−(4−ヒドロキシフェニル)エチルアルコー
ル、8g (20mmol)のグルコースペンタアセテー
ト、モレキュラーシーブス2g を入れ、室温下に約1時
間撹拌した後、三フッ素化ホウ素ジエチルエーテル溶液
1mlを加え、さらに3時間撹拌した。20mlの水を加え
た後、モレキュラーシーブスをろ別した。ろ液から酢酸
エチルにて有機層を抽出した。酢酸エチル層を1N水酸
化ナトリウムにて洗浄し、未反応の2−(4−ヒドロキ
シフェニル)エチルアルコールを除去した。酢酸エチル
層を精製水にて洗浄した後、硫酸ナトリウムにて乾燥し
た。硫酸ナトリウムを除去した後、減圧下に有機溶媒を
除去することにより、p−(2−ヒドロキシエチル)フ
ェニルテトラアセチル−D−グルコシドを得た。
2.76 g (16.8 mmol) was added to a mixed solution of 40 ml of dehydrated toluene and 10 ml of dehydrated ethyl ether.
1) 2- (4-hydroxyphenyl) ethyl alcohol, 8 g (20 mmol) of glucose pentaacetate and 2 g of molecular sieves were added, and the mixture was stirred at room temperature for about 1 hour, and 1 ml of boron trifluoride diethyl ether solution was added. The mixture was further stirred for 3 hours. After adding 20 ml of water, the molecular sieves were filtered off. The organic layer was extracted from the filtrate with ethyl acetate. The ethyl acetate layer was washed with 1N sodium hydroxide to remove unreacted 2- (4-hydroxyphenyl) ethyl alcohol. The ethyl acetate layer was washed with purified water and dried over sodium sulfate. After removing sodium sulfate, the organic solvent was removed under reduced pressure to obtain p- (2-hydroxyethyl) phenyltetraacetyl-D-glucoside.

【0021】p−(2−ヒドロキシエチル)フェニルテ
トラアセチル−D−グルコシドを常法に従って、ナトリ
ウムメトキシドを用いて、脱アセチル化をした後、イオ
ン交換樹脂(アンバーライト)を用いて中和した。イオ
ン交換樹脂をろ別した後、減圧下に溶媒を除去し、p−
(2−ヒドロキシエチル)フェニル−D−グルコシド
(β体)3.4g を得た。この構造は13C−NMRスペ
クトルおよび赤外吸収スペクトルにより確認した。図1
に本発明で得たp−(2−ヒドロキシエチル)フェニル
−D−グルコシド(β体)の13C−NMRスペクトルを
示す。
According to a conventional method, p- (2-hydroxyethyl) phenyltetraacetyl-D-glucoside was deacetylated using sodium methoxide, and then neutralized using an ion exchange resin (Amberlite). . After filtering off the ion exchange resin, the solvent was removed under reduced pressure, and p-
3.4 g of (2-hydroxyethyl) phenyl-D-glucoside (β form) was obtained. This structure was confirmed by a 13 C-NMR spectrum and an infrared absorption spectrum. FIG.
13 shows a 13 C-NMR spectrum of p- (2-hydroxyethyl) phenyl-D-glucoside (β form) obtained in the present invention.

【0022】なお、合成例1に準じて、表1の「試料」
欄に示す、本発明に係わる、配糖体を得た。
In addition, according to Synthesis Example 1, "sample" in Table 1 was used.
Glycosides according to the present invention shown in the column were obtained.

【0023】試験例1:メラニン生成抑制試験〔インビ
トロ(in vitro)試験〕 色素細胞でのメラニン生成抑制試験は、B16メラノー
マ細胞(3×105 個)を直径90mmのプラスチックプ
レートにまき、同時に試験試料を3×10-5M濃度(試
験濃度はモル濃度に統一した)で添加し、72時間培養
を行った。培養は10%FBSを含むMEM(2mMテ
オフィリン含有)培地にて行った。培養終了後に常法に
従い、細胞を剥離し洗浄を行った後、遠心分離を行っ
た。得られた細胞を5%TCA、エタノール:エーテル
=3:1、さらにエーテルの順に洗浄した。乾燥後、ソ
ルエン350に溶解し400nmにて吸光度測定するこ
とにより、メラニン量を測定した。吸光度が低い程、メ
ラニン生成抑制効果が大きいことを示す。なお、比較例
として、メラニン生成抑制効果を有していることが知ら
れているハイドロキノン配糖体(アルブチン)を用い
た。
Test Example 1 Melanin Production Inhibition Test [In Vitro Test] In the melanin production inhibition test using pigment cells, B16 melanoma cells (3 × 10 5 cells) were spread on a plastic plate having a diameter of 90 mm and simultaneously tested. The sample was added at a concentration of 3 × 10 −5 M (the test concentration was unified to the molar concentration), and the cells were cultured for 72 hours. The culture was performed in a MEM (containing 2 mM theophylline) medium containing 10% FBS. After completion of the culture, the cells were detached and washed according to a conventional method, and then centrifuged. The obtained cells were washed with 5% TCA, ethanol: ether = 3: 1, and then with ether. After drying, the melanin content was measured by dissolving in Solen 350 and measuring the absorbance at 400 nm. The lower the absorbance, the greater the melanin production inhibitory effect. As a comparative example, a hydroquinone glycoside (arbutin) known to have a melanin production inhibitory effect was used.

【0024】測定結果を表1に示す。Table 1 shows the measurement results.

【0025】[0025]

【表1】 [Table 1]

【0026】表1の結果から、本発明のメラニン生成抑
制剤は、細胞の増殖を妨げることなく(安全性が高いこ
とを意味する)、メラニン生成を抑制することが明らか
になった。また、その程度は医薬品・化粧品等に汎用さ
れているアルブチンに比べて吸光度が低く、すなわちメ
ラニン生成抑制効果に優れていることが判った。この、
インビトロ試験成績より、本発明の特定の配糖体は、美
白化粧料の主剤として、例えば医薬品、医薬部外品、化
粧品などに配合することが可能であることが、再確認で
きた。
From the results shown in Table 1, it was clarified that the melanin production inhibitor of the present invention inhibits melanin production without inhibiting cell proliferation (meaning high safety). In addition, it was found that the degree of absorbance was lower than that of arbutin, which is widely used in pharmaceuticals, cosmetics, and the like, that is, the melanin production inhibitory effect was excellent. this,
From the results of the in vitro test, it was reconfirmed that the specific glycoside of the present invention can be added to, for example, pharmaceuticals, quasi-drugs, cosmetics, and the like as a main component of whitening cosmetics.

【0027】試験例2:皮膚色素沈着回復試験〔インビ
ボ(in vivo) 試験〕 被験者一群20名の上腕内側部皮膚に、紫外線照射部位
を2ケ 所設定(2×2cm)し、最小紅斑量の中波長領域
紫外線(デルマレイN−DMR型、東芝医療用品製)を
3日間連続照射した。照射終了後より、一方には試料製
剤を1日3回ずつ4週間連続で塗布し、他方にはベース
(本製剤から主剤を除いたもの)を塗布した。紫外線照
射から4週間後にそれぞれの部分を肉眼判定により、ベ
ース塗布部と試料製剤塗布部の色素沈着の程度の比較を
行った。表2の評価基準により、ベース塗布部と比較し
て色素沈着の回復度を評価した。なお、評価は20名の
評価点の平均値で示す。
Test Example 2: Skin Pigmentation Recovery Test [In Vivo Test] Two ultraviolet irradiation sites (2 × 2 cm) were set on the inner skin of the upper arm of a group of 20 subjects, and the minimum erythema amount was measured. Irradiation was performed continuously for 3 days with ultraviolet rays in the middle wavelength region (Dermalei N-DMR, manufactured by Toshiba Medical Products). From the end of the irradiation, one was coated with the sample preparation three times a day for four consecutive weeks, and the other was coated with the base (the main preparation was removed from the preparation). Four weeks after the ultraviolet irradiation, the degree of pigmentation between the base application part and the sample preparation application part was compared by visual judgment of each part. According to the evaluation criteria in Table 2, the degree of recovery of pigmentation was evaluated in comparison with the base coated part. In addition, evaluation is shown by the average value of the evaluation point of 20 persons.

【0028】[0028]

【表2】 [Table 2]

【0029】実施例1〜3、比較例1(クリーム) 表3における処方で、常法によりクリームを作製した。Examples 1 to 3 and Comparative Example 1 (Cream) Creams were prepared according to the formulation shown in Table 3 by a conventional method.

【0030】[0030]

【表3】 [Table 3]

【0031】実施例1〜3、比較例1の皮膚色素沈着回
復試験の結果を表4に示す。
Table 4 shows the results of the skin pigmentation recovery tests of Examples 1 to 3 and Comparative Example 1.

【0032】[0032]

【表4】 [Table 4]

【0033】表4から、本発明の実施例は、しみ、そば
かすを改善する効果に優れることは明らかである。特
に、p−(2−ヒドロキシエチル)フェニル−D−グル
コシド(β体)を配合した、実施例1は効果が顕著であ
った。なお、試験期間中、被験者の試料製剤塗布部位に
皮膚刺激反応は認められず、本発明品は製剤の形態にお
いても安全であることが確認できた。
From Table 4, it is clear that the examples of the present invention are excellent in the effect of improving spots and freckles. In particular, Example 1 in which p- (2-hydroxyethyl) phenyl-D-glucoside (β-form) was blended had a remarkable effect. During the test period, no skin irritation reaction was observed at the site where the sample preparation was applied to the test subject, confirming that the product of the present invention is safe even in the form of the preparation.

【0034】実施例4(乳液) 表5における処方で、常法により乳液を作製した。Example 4 (Emulsion) An emulsion was prepared according to the formulation shown in Table 5 by a conventional method.

【0035】[0035]

【表5】 [Table 5]

【0036】実施例5(化粧水) 表6における処方で、常法により化粧水を作製した。Example 5 (Lotion) A lotion was prepared according to the formulation shown in Table 6 by a conventional method.

【0037】[0037]

【表6】 [Table 6]

【0038】実施例4〜5の皮膚色素沈着回復試験の結
果を表7に示す。
Table 7 shows the results of the skin pigmentation recovery tests of Examples 4 and 5.

【0039】[0039]

【表7】 [Table 7]

【0040】表7から、実施例4〜5は、しみ、そばか
すの改善効果に優れることは明らかである。
From Table 7, it is clear that Examples 4 and 5 are excellent in the effect of improving spots and freckles.

【0041】[0041]

【発明の効果】以上記載の如く、本発明の配糖体は、優
れたメラニン生成抑制作用を示し、またその安全性も高
かった。一方、本発明の配糖体を配合した製剤は、紫外
線に曝露されたことによって生じた皮膚の色素沈着(し
み、そばかすなど)を改善する優れた効果を示した。し
たがって、本発明の配糖体は、紫外線などによるメラニ
ンの過剰生成によるしみ、そばかす形成を予防する化粧
品や医薬部外品への配合、色素沈着症の治療、予防剤と
しての薬品への利用が可能な、有用なメラニン生成抑制
剤を提供することは明かである。
As described above, the glycoside of the present invention exhibited an excellent melanin production-inhibiting action, and its safety was also high. On the other hand, the preparation containing the glycoside of the present invention exhibited an excellent effect of improving skin pigmentation (staining, freckles, etc.) caused by exposure to ultraviolet light. Therefore, the glycosides of the present invention can be used in cosmetics and quasi-drugs to prevent the formation of spots due to excessive production of melanin due to ultraviolet rays, freckles, the treatment of pigmentation, and the use as drugs as prophylactic agents. It is clear that it provides a possible and useful melanogenesis inhibitor.

【図面の簡単な説明】[Brief description of the drawings]

【図1】本発明の合成例1で得られたp−(2−ヒドロ
キシエチル)フェニル−D−グルコシド(β体)の13
−NMRスペクトルを示す図である。
FIG. 1 shows 13 C of p- (2-hydroxyethyl) phenyl-D-glucoside (β-form) obtained in Synthesis Example 1 of the present invention.
It is a figure which shows -NMR spectrum.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 下記一般式 【化1】 (但し、式中Rは単糖類、少糖類の残基から選ばれる基
である。)からなるメラニン生成抑制剤。
[Claim 1] The following general formula: (Wherein, R is a group selected from the residues of monosaccharides and oligosaccharides).
【請求項2】 請求項1に記載のメラニン生成抑制剤を
含有することを特徴とする美白化粧料。
2. A whitening cosmetic comprising the melanin production inhibitor according to claim 1.
JP35418396A 1996-12-17 1996-12-17 Suppressant for melanogenesis and beautifying and whitening cosmetic Pending JPH10175820A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP35418396A JPH10175820A (en) 1996-12-17 1996-12-17 Suppressant for melanogenesis and beautifying and whitening cosmetic
TW86115777A TW464501B (en) 1996-12-17 1997-10-24 Melanine formation inhibitor and their beautiful-white cosmetic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35418396A JPH10175820A (en) 1996-12-17 1996-12-17 Suppressant for melanogenesis and beautifying and whitening cosmetic

Publications (1)

Publication Number Publication Date
JPH10175820A true JPH10175820A (en) 1998-06-30

Family

ID=18435852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP35418396A Pending JPH10175820A (en) 1996-12-17 1996-12-17 Suppressant for melanogenesis and beautifying and whitening cosmetic

Country Status (1)

Country Link
JP (1) JPH10175820A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003238585A (en) * 2002-02-08 2003-08-27 Ogawa & Co Ltd Naphthol glycoside and bleaching composition for external use containing the same
JP2006176420A (en) * 2004-12-21 2006-07-06 Univ Of Tokushima Tyrosinase activity inhibitor, method for producing the same and use
CN100427497C (en) * 2006-08-21 2008-10-22 浙江大学 Method of chemical synthesizing hongjingtian glycoside
CN111110581A (en) * 2019-12-31 2020-05-08 蓝脑科技(厦门)有限公司 Novel agaro-oligosaccharide composition with whitening function improving function and application thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003238585A (en) * 2002-02-08 2003-08-27 Ogawa & Co Ltd Naphthol glycoside and bleaching composition for external use containing the same
JP2006176420A (en) * 2004-12-21 2006-07-06 Univ Of Tokushima Tyrosinase activity inhibitor, method for producing the same and use
CN100427497C (en) * 2006-08-21 2008-10-22 浙江大学 Method of chemical synthesizing hongjingtian glycoside
CN111110581A (en) * 2019-12-31 2020-05-08 蓝脑科技(厦门)有限公司 Novel agaro-oligosaccharide composition with whitening function improving function and application thereof
CN111110581B (en) * 2019-12-31 2022-09-27 蓝脑科技(厦门)有限公司 Novel agaro-oligosaccharide composition with whitening function improving function and application thereof

Similar Documents

Publication Publication Date Title
US20050226828A1 (en) Method for whitening human skin
JP4992164B2 (en) Cosmetic composition
WO2016177908A2 (en) Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same
JP3340935B2 (en) Melanin production inhibitor and whitening cosmetic
JP3340928B2 (en) Melanin production inhibitor and whitening cosmetic
WO2000057889A1 (en) Skin preparations for external use
JP3192376B2 (en) Melanin production inhibitor and whitening cosmetic
US7393937B2 (en) N-acetylglucosamine derivatives and use thereof
JPH10175820A (en) Suppressant for melanogenesis and beautifying and whitening cosmetic
JP3340930B2 (en) Melanin production inhibitor and whitening cosmetic
JPH07157494A (en) New isoflavone glycoside and cosmetic containing the same
JPWO2010030000A1 (en) Whitening agent and skin external preparation for whitening
JP2010037251A (en) Skin external preparation
WO1997035557A1 (en) External skin-care composition
JPH0580449B2 (en)
JP3976943B2 (en) Whitening cosmetics
JP3034057B2 (en) Sugar-cinnamic acid derivatives and UV absorbers
JP2000095642A (en) Bleaching preparation
JPH0977660A (en) Melanogenesis suppressing agent and skin preparation for external use
JP3113407B2 (en) Cosmetics
JP2000095641A (en) Bleaching preparation
JPH09301990A (en) Sesamol glucide and preparation for external use for skin
JP2002501914A (en) Benzo [B] pyran derivatives useful as external preparations for skin
JP3140575B2 (en) Benzophenone derivative, ultraviolet absorber and external skin preparation containing the same
JP2000109408A (en) Skin whitening cosmetic